Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium

The soaring demand for lithium is driven by worldwide demand for electric vehicles (EVs). Lithium is ideal for electric cars. It's lightweight, stores lots of energy and is rechargeable. Sales of EVs are expected to increase 10-fold by 2030 and estimates are that 1 in 2 cars sold will be electric by 2040.

See how EV demand is creating new opportunities

HALO Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 2.30%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $6,463,598.50

Halozyme Therapeutics Insider Trading History Chart

Halozyme Therapeutics Share Price & Price History

^$38.58

▼ -0.24 (-0.62%)

As of 09/26/2022 03:46 PM ET

Days: 30 | 90 | 365

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium

From Investing Trends | Ad

See how EV demand is creating new opportunities

Halozyme Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/8/2021	Helen Torley	CEO	Sell	50,000	$39.82	$1,991,000.00
11/5/2021	Connie Matsui	Director	Sell	32,000	$40.38	$1,292,160.00
10/4/2021	Helen Torley	CEO	Sell	50,000	$40.09	$2,004,500.00
10/1/2021	Michael J. LaBarre	SVP	Sell	29,450	$39.93	$1,175,938.50
9/7/2021	Helen Torley	CEO	Sell	50,000	$42.38	$2,119,000.00	587,160
8/25/2021	Jean-Pierre Bizzari	Director	Sell	35,000	$41.01	$1,435,350.00
8/10/2021	Helen Torley	CEO	Sell	50,000	$41.11	$2,055,500.00
7/6/2021	Helen Torley	CEO	Sell	50,000	$45.97	$2,298,500.00	587,160
7/1/2021	Michael J. LaBarre	SVP	Sell	40,315	$45.70	$1,842,395.50
6/7/2021	Helen Torley	CEO	Sell	50,000	$39.66	$1,983,000.00	587,160
5/11/2021	Helen Torley	CEO	Sell	50,000	$43.02	$2,151,000.00	587,160
4/14/2021	Kenneth J. Kelley	Director	Sell	5,000	$45.00	$225,000.00	179,833
4/5/2021	Helen Torley	CEO	Sell	50,000	$42.55	$2,127,500.00	587,160
4/1/2021	Michael J. LaBarre	SVP	Sell	28,689	$42.56	$1,221,003.84
3/1/2021	Helen Torley	CEO	Sell	50,000	$46.19	$2,309,500.00	587,160
3/1/2021	Kenneth J. Kelley	Director	Sell	5,000	$45.34	$226,700.00	185,333
3/1/2021	Michael J. LaBarre	SVP	Sell	18,324	$45.81	$839,422.44	129,330
2/1/2021	Helen Torley	CEO	Sell	50,000	$47.84	$2,392,000.00	520,522
2/1/2021	Kenneth J. Kelley	Director	Sell	5,000	$48.12	$240,600.00	190,079
1/4/2021	Kenneth J. Kelley	Director	Sell	5,000	$42.91	$214,550.00	195,123
12/21/2020	Michael J. LaBarre	SVP	Sell	12,000	$42.58	$510,960.00	123,400
12/7/2020	Kenneth J. Kelley	Director	Sell	35,086	$41.00	$1,438,526.00	199,833
12/2/2020	Kenneth J. Kelley	Director	Sell	31,792	$41.00	$1,303,472.00	234,919
11/27/2020	Kenneth J. Kelley	Director	Sell	10,000	$41.25	$412,500.00	276,711
11/25/2020	Helen Torley	CEO	Sell	50,000	$40.73	$2,036,500.00	530,522
11/25/2020	Jeffrey William Henderson	Director	Sell	24,498	$40.08	$981,879.84	47,609
11/20/2020	Michael J. LaBarre	SVP	Sell	12,000	$38.76	$465,120.00	142,689
10/20/2020	Michael J. LaBarre	SVP	Sell	12,000	$30.43	$365,160.00	146,800
9/21/2020	Michael J. LaBarre	SVP	Sell	12,000	$26.91	$322,920.00	158,800
9/11/2020	Connie Matsui	Director	Sell	32,000	$27.06	$865,920.00	216,753
8/20/2020	Michael J. LaBarre	SVP	Sell	12,000	$28.30	$339,600.00	170,800
8/13/2020	James M. Daly	Director	Sell	34,337	$29.12	$999,893.44	31,365
7/20/2020	Michael J. LaBarre	SVP	Sell	12,000	$29.01	$348,120.00	182,800
5/20/2020	Michael J. LaBarre	SVP	Sell	21,387	$23.80	$509,010.60	197,574
3/19/2020	Kenneth J. Kelley	Director	Buy	52,629	$14.23	$748,910.67	242,467

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium

From Investing Trends | Ad

See how EV demand is creating new opportunities

SEC Filings (Institutional Ownership Changes) for Halozyme Therapeutics (NASDAQ:HALO)

91.72% of Halozyme Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Halozyme Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
9/16/2022	Federated Hermes Inc.	83,547	$3.68M	0.0%	-3.0%	0.061%
9/12/2022	Hussman Strategic Advisors Inc.	9,300	$0.41M	0.1%	N/A	0.007%
9/2/2022	Cim Investment Management Inc.	6,199	$0.27M	0.1%	+21.4%	0.004%
8/30/2022	Verition Fund Management LLC	14,877	$0.66M	0.0%	N/A	0.011%
8/23/2022	Captrust Financial Advisors	3,902	$0.17M	0.0%	+15.6%	0.003%
8/22/2022	Sheets Smith Investment Management	12,066	$0.51M	0.6%	N/A	0.009%
8/22/2022	Legal & General Group Plc	272,125	$11.97M	0.0%	-6.7%	0.198%
8/22/2022	ExodusPoint Capital Management LP	160,279	$7.05M	0.1%	+25.3%	0.116%
8/19/2022	Walleye Capital LLC	11,372	$0.50M	0.0%	N/A	0.008%
8/17/2022	Advisory Research Inc.	35,555	$1.57M	0.1%	N/A	0.026%
8/16/2022	First Republic Investment Management Inc.	159,742	$7.03M	0.0%	-22.8%	0.116%
8/16/2022	Captrust Financial Advisors	3,902	$0.17M	0.0%	+15.6%	0.003%
8/16/2022	Castleark Management LLC	203,940	$8.97M	0.5%	N/A	0.148%
8/16/2022	United Services Automobile Association	15,061	$0.66M	0.0%	N/A	0.011%
8/16/2022	Colony Group LLC	81,315	$3.58M	0.1%	+0.6%	0.059%
8/16/2022	Bank of Marin	28,864	$1.27M	1.1%	+14.0%	0.021%
8/16/2022	Thrivent Financial for Lutherans	1,326,058	$58.35M	0.2%	-9.6%	0.962%
8/16/2022	Price T Rowe Associates Inc. MD	1,563,357	$68.79M	0.0%	-0.1%	1.135%
8/16/2022	Prudential Financial Inc.	315,229	$13.88M	0.0%	+269.6%	0.229%
8/16/2022	Penn Capital Management Company LLC	299,825	$13.19M	1.4%	+33.3%	0.218%
8/16/2022	Driehaus Capital Management LLC	1,282,492	$56.43M	0.9%	+51.9%	0.931%
8/15/2022	AQR Capital Management LLC	54,200	$2.39M	0.0%	-5.7%	0.039%
8/15/2022	Macquarie Group Ltd.	2,520,531	$110.90M	0.1%	+1.9%	1.829%
8/15/2022	Point72 Hong Kong Ltd	3,553	$0.16M	0.0%	N/A	0.003%
8/15/2022	Cubist Systematic Strategies LLC	202,355	$8.90M	0.1%	+379.7%	0.147%
8/15/2022	Millennium Management LLC	66,984	$2.95M	0.0%	+5.9%	0.049%
8/15/2022	Zebra Capital Management LLC	6,877	$0.30M	0.9%	+9.7%	0.005%
8/15/2022	Voya Investment Management LLC	109,552	$4.82M	0.0%	-56.6%	0.080%
8/15/2022	Quantamental Technologies LLC	10,546	$0.46M	0.2%	+31.6%	0.008%
8/15/2022	Natixis Advisors L.P.	37,840	$1.67M	0.0%	+25.2%	0.027%
8/15/2022	UBS Asset Management Americas Inc.	176,864	$7.78M	0.0%	+5.6%	0.128%
8/13/2022	Quantbot Technologies LP	6,500	$0.29M	0.0%	N/A	0.005%
8/13/2022	Rothschild & Co. Asset Management US Inc.	183,771	$8.09M	0.1%	-0.3%	0.133%
8/13/2022	Teacher Retirement System of Texas	21,920	$0.96M	0.0%	-20.8%	0.016%
8/13/2022	Virtu Financial LLC	19,102	$0.84M	0.1%	N/A	0.014%
8/13/2022	Zurcher Kantonalbank Zurich Cantonalbank	16,734	$0.74M	0.0%	-11.1%	0.012%
8/13/2022	Renaissance Technologies LLC	485,200	$21.35M	0.0%	+133.6%	0.352%
8/13/2022	Vanguard Personalized Indexing Management LLC	5,582	$0.25M	0.0%	N/A	0.004%
8/13/2022	American International Group Inc.	289,997	$12.76M	0.1%	-5.2%	0.210%
8/12/2022	Natixis	67,900	$2.99M	0.0%	N/A	0.049%
8/12/2022	Northern Trust Corp	2,153,942	$94.77M	0.0%	-4.0%	1.561%
8/12/2022	Virtus ETF Advisers LLC	5,324	$0.23M	0.1%	-50.4%	0.004%
8/12/2022	Ensign Peak Advisors Inc	42,570	$1.87M	0.0%	-7.7%	0.031%
8/12/2022	First Light Asset Management LLC	941,245	$41.42M	4.8%	-41.1%	0.682%
8/12/2022	LPL Financial LLC	16,497	$0.73M	0.0%	+14.1%	0.012%
8/12/2022	Fox Run Management L.L.C.	7,639	$0.34M	0.2%	N/A	0.006%
8/12/2022	Rafferty Asset Management LLC	87,152	$3.84M	0.0%	-43.4%	0.063%
8/12/2022	FMR LLC	1,076,346	$47.36M	0.0%	+19.4%	0.781%
8/12/2022	Artisan Partners Limited Partnership	6,365,361	$280.08M	0.5%	-31.4%	4.620%
8/12/2022	Kiwi Wealth Investments Limited Partnership	18,707	$0.82M	0.1%	N/A	0.014%
8/12/2022	Corient Capital Partners LLC	4,627	$0.20M	0.0%	N/A	0.003%
8/12/2022	United Capital Financial Advisers LLC	17,468	$0.77M	0.0%	+93.8%	0.013%
8/12/2022	Franklin Resources Inc.	688,216	$30.28M	0.0%	+1,548.8%	0.499%
8/12/2022	Rhumbline Advisers	436,442	$19.20M	0.0%	+5.0%	0.316%
8/11/2022	AlphaCrest Capital Management LLC	43,731	$1.92M	0.1%	+74.8%	0.032%
8/11/2022	Cetera Advisor Networks LLC	5,522	$0.24M	0.0%	N/A	0.004%
8/11/2022	O Shaughnessy Asset Management LLC	10,947	$0.48M	0.0%	+6.4%	0.008%
8/11/2022	Axiom Investors LLC DE	86,925	$3.83M	0.1%	+34.7%	0.063%
8/11/2022	EP Wealth Advisors LLC	5,500	$0.24M	0.0%	-35.3%	0.004%
8/11/2022	UBS Group AG	78,872	$3.47M	0.0%	-13.2%	0.057%
8/11/2022	Martingale Asset Management L P	5,220	$0.23M	0.0%	N/A	0.004%
8/11/2022	Brown Brothers Harriman & Co.	801	$35K	0.0%	N/A	0.001%
8/11/2022	Harvest Fund Management Co. Ltd	1,973	$87K	0.0%	N/A	0.001%
8/10/2022	Synovus Financial Corp	53,525	$2.35M	0.0%	-31.0%	0.039%
8/10/2022	Kennedy Capital Management Inc.	602,011	$26.49M	0.7%	+7.1%	0.436%
8/10/2022	Mutual of America Capital Management LLC	204,745	$9.01M	0.1%	+59.5%	0.148%
8/10/2022	Mackenzie Financial Corp	62,256	$2.74M	0.0%	-19.0%	0.045%
8/10/2022	MGO One Seven LLC	7,741	$0.34M	0.0%	N/A	0.006%
8/10/2022	Nwam LLC	4,950	$0.23M	0.0%	N/A	0.004%
8/10/2022	Eagle Asset Management Inc.	1,394,737	$61.37M	0.4%	+16.4%	1.011%
8/10/2022	California Public Employees Retirement System	264,136	$11.62M	0.0%	-7.6%	0.191%
8/10/2022	Principal Financial Group Inc.	634,560	$27.92M	0.0%	+29.4%	0.460%
8/10/2022	William Blair Investment Management LLC	4,566,871	$200.94M	0.7%	-14.5%	3.311%
8/10/2022	Cerity Partners LLC	5,953	$0.26M	0.0%	N/A	0.004%
8/10/2022	Corbett Road Capital Management LLC	16,525	$0.73M	1.2%	N/A	0.012%
8/10/2022	Inspire Investing LLC	4,741	$0.21M	0.0%	-19.9%	0.003%
8/9/2022	Swiss National Bank	324,400	$14.27M	0.0%	+2.6%	0.235%
8/9/2022	Pictet Asset Management SA	121,867	$5.36M	0.0%	-46.6%	0.088%
8/9/2022	Lazard Asset Management LLC	6,003	$0.26M	0.0%	+3,010.4%	0.004%
8/9/2022	Shell Asset Management Co.	11,460	$0.50M	0.0%	+42.6%	0.008%
8/8/2022	AdvisorShares Investments LLC	19,472	$0.86M	0.2%	N/A	0.014%
8/8/2022	Advisors Asset Management Inc.	34,770	$1.53M	0.0%	+26.7%	0.025%
8/8/2022	Walleye Capital LLC	11,372	$0.50M	0.0%	N/A	0.008%
8/8/2022	Baird Financial Group Inc.	70,688	$3.11M	0.0%	+5.5%	0.051%
8/8/2022	Oppenheimer & Co. Inc.	7,544	$0.33M	0.0%	N/A	0.005%
8/8/2022	TownSquare Capital LLC	10,458	$0.46M	0.0%	-12.3%	0.008%
8/8/2022	Bay Colony Advisory Group Inc d b a Bay Colony Advisors	4,450	$0.22M	0.1%	N/A	0.003%
8/8/2022	Texas Permanent School Fund	100,039	$4.40M	0.1%	+0.2%	0.073%
8/8/2022	Verdence Capital Advisors LLC	15,528	$0.68M	0.1%	+10.7%	0.011%
8/8/2022	State of Michigan Retirement System	35,038	$1.54M	0.0%	-2.0%	0.025%
8/8/2022	Meeder Asset Management Inc.	741	$33K	0.0%	+223.6%	0.001%
8/8/2022	Keybank National Association OH	5,333	$0.24M	0.0%	-22.9%	0.004%
8/8/2022	Hancock Whitney Corp	9,211	$0.41M	0.0%	-6.8%	0.007%
8/5/2022	State Board of Administration of Florida Retirement System	51,100	$2.25M	0.0%	-4.6%	0.037%
8/5/2022	M&T Bank Corp	102,326	$4.50M	0.0%	+100.0%	0.074%
8/5/2022	Connor Clark & Lunn Investment Management Ltd.	37,513	$1.65M	0.0%	N/A	0.027%
8/5/2022	Ifrah Financial Services Inc.	7,048	$0.31M	0.1%	N/A	0.005%
8/5/2022	Loomis Sayles & Co. L P	2,172,478	$95.59M	0.2%	-0.6%	1.575%
8/5/2022	Los Angeles Capital Management LLC	195,613	$8.61M	0.0%	+0.9%	0.142%
8/4/2022	Steward Partners Investment Advisory LLC	1,300	$57K	0.0%	N/A	0.001%

Data available starting January 2016

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Today's Range

Now: $38.58

$38.27

$39.03

50 Day Range

MA: $43.75

$38.53

$51.70

52 Week Range

Now: $38.58

$31.36

$52.98

Volume

22,600 shs

Average Volume

1,130,159 shs

Market Capitalization

$5.32 billion

P/E Ratio

15.25

Dividend Yield

N/A

Beta

1.25

Who are the company insiders with the largest holdings of Halozyme Therapeutics?: Halozyme Therapeutics' top insider shareholders include:
Helen Torley (CEO)
Kenneth J Kelley (Director)
Michael J Labarre (SVP)
Jeffrey William Henderson (Director)
Connie Matsui (Director)
Jean-Pierre Bizzari (Director)
Learn More about top insider investors at Halozyme Therapeutics.
Who are the major institutional investors of Halozyme Therapeutics?: Halozyme Therapeutics' top institutional investors include:
Artisan Partners Limited Partnership — 4.62%
William Blair Investment Management LLC — 3.31%
Macquarie Group Ltd. — 1.83%
Loomis Sayles & Co. L P — 1.57%
Northern Trust Corp — 1.56%
Victory Capital Management Inc. — 1.30%
Learn More about top institutional investors of Halozyme Therapeutics stock.
Which major investors are selling Halozyme Therapeutics stock?: Within the last quarter, HALO stock was sold by these institutional investors:
Artisan Partners Limited Partnership
William Blair Investment Management LLC
First Light Asset Management LLC
Voya Investment Management LLC
Thrivent Financial for Lutherans
Candriam S.C.A.
EFG Asset Management North America Corp.
Pictet Asset Management SA
In the last year, company insiders that have sold Halozyme Therapeutics company stock include:
Helen Torley (CEO)
Kenneth J Kelley (Director)
Michael J Labarre (SVP)
Learn More investors selling Halozyme Therapeutics stock.
Which major investors are buying Halozyme Therapeutics stock?: Within the last quarter, HALO stock was acquired by institutional investors including:
Victory Capital Management Inc.
Franklin Resources Inc.
Driehaus Capital Management LLC
Lisanti Capital Growth LLC
Renaissance Technologies LLC
Covington Capital Management
Prudential Financial Inc.
Castleark Management LLC

Investor Alert: EV Initiatives Create Unsustainable Demand For Lithium

From Investing Trends | Ad

See how EV demand is creating new opportunities

HALO Insider Trading

Halozyme Therapeutics Insider Trading History Chart

Halozyme Therapeutics Share Price & Price History

Halozyme Therapeutics Insider Trading History

SEC Filings (Institutional Ownership Changes) for Halozyme Therapeutics (NASDAQ:HALO)

Institutional Buying and Selling by Quarter

Halozyme Therapeutics Institutional Trading History

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Who are the company insiders with the largest holdings of Halozyme Therapeutics?

Who are the major institutional investors of Halozyme Therapeutics?

Which major investors are selling Halozyme Therapeutics stock?

Which major investors are buying Halozyme Therapeutics stock?